How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

443 results for

Absolute Lymphocyte Count Estimation of CD4 Count

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Absolute Lymphocyte Count Estimation of CD4 Count

Absolute Lymphocyte Count Estimation of CD4 Count Absolute Lymphocyte Count Estimation of CD4 Count Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Absolute Lymphocyte Count Estimation of CD4 Count Absolute Lymphocyte Count Estimation of CD4 Count Aka: Absolute Lymphocyte Count Estimation of CD4 Count , ALC-Based CD4 Estimate II. Indication Estimate whether is less than 200 in an HIV patient III. Technique Measure with differential Determine the absolute number of s (absolute or ALC) IV. Interpretation Absolute (ALC) <1000 cells/mm3 is highly likely to be less than 200 cells/mm3 Absolute (ALC) 1000 to 2000 cells/mm3 Indeterminate range

2018 FP Notebook

2. Absolute Lymphocyte Count as a Surrogate Marker of CD4 Count in Monitoring HIV Infected Individuals: A Prospective Study (PubMed)

Absolute Lymphocyte Count as a Surrogate Marker of CD4 Count in Monitoring HIV Infected Individuals: A Prospective Study CD4 cell count has been proposed to be substituted by Absolute lymphocyte count in monitoring HIV infected individuals as methods of CD4 cell count and plasma viral estimation require expensive, specialized equipments and highly trained personnel.To assess the clinical utility of the Absolute Lymphocyte Count (ALC) to serve as a surrogate marker for predicting a CD4 count (...) < 200 cells/μl in patients with HIV infection in resource poor countries.A prospective study of 61 patients with HIV/AIDS was conducted. Sensitivity, specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV) of various ALC cut-offs were computed for CD4 cell count < 200 cells/μl for age < 30 or age ≥ 30 years. Pearson correlation, Linear regression and Receiver Operating Characteristics (ROC), were used.For patients aged ≥ 30 years, sensitivity, specificity, positive and negative

Full Text available with Trip Pro

2016 Journal of clinical and diagnostic research : JCDR

3. The absolute lymphocyte count accurately estimates CD4 counts in HIV-infected adults with virologic suppression and immune reconstitution. (PubMed)

The absolute lymphocyte count accurately estimates CD4 counts in HIV-infected adults with virologic suppression and immune reconstitution. The clinical value of monitoring CD4 counts in immune reconstituted, virologically suppressed HIV-infected patients is limited. We investigated if absolute lymphocyte counts (ALC) from an automated blood counting machine could accurately estimate CD4 counts.CD4 counts, ALC and HIV viral load (VL) were extracted from an electronic laboratory database for all (...) -ALCs available for analysis. 98.3% of CD4 estimates were within 50% of the actual value. 83.3% within 25% and 40.5% within 10%. The error pattern was approximately symmetrically distributed around a mean of -6.5%, but significant peaked and with mild positive skew (kurtosis 4.45, skewness 1.07). Causes for these errors were explored. Variability between lymphocyte counts measured by ALC and flow cytometry did not follow an apparent pattern, and contributed to 32% of the total error (median absolute

Full Text available with Trip Pro

2014 Journal of the International AIDS Society

4. Absolute Lymphocyte Count Estimation of CD4 Count

Absolute Lymphocyte Count Estimation of CD4 Count Absolute Lymphocyte Count Estimation of CD4 Count Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Absolute Lymphocyte Count Estimation of CD4 Count Absolute Lymphocyte Count Estimation of CD4 Count Aka: Absolute Lymphocyte Count Estimation of CD4 Count , ALC-Based CD4 Estimate II. Indication Estimate whether is less than 200 in an HIV patient III. Technique Measure with differential Determine the absolute number of s (absolute or ALC) IV. Interpretation Absolute (ALC) <1000 cells/mm3 is highly likely to be less than 200 cells/mm3 Absolute (ALC) 1000 to 2000 cells/mm3 Indeterminate range

2015 FP Notebook

5. Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas

lymphocytes [TIL], lymphokine-activated killer [LAK] or gene therapy), or hormonal therapy for their brain tumor; prior Gliadel wafers are allowed; glucocorticoid therapy is allowed Patients must have CD4 =< 300 cells/mm^3 in the last week (7 days) of standard radiation + temozolomide treatment (58-60 Gy radiation with temozolomide 75 mg/m2 daily during radiation) Absolute neutrophil count >= 1,500/mcL Platelets >= 100,000/mcL Hemoglobin >= 9 g/dL Total bilirubin =< institutional upper limit of normal (...) -hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide Actual Study Start Date : October 30, 2018 Estimated Primary Completion Date : November 20, 2021 Estimated Study Completion Date : August 15, 2022 Resource links provided by the National Library of Medicine resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Arm A - Low Dexamethasone (LD) Patients receive single dose

2016 Clinical Trials

6. Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial. (PubMed)

. Five participants, all in the 3TC/FTC arm, reached the primary endpoint for absolute CD4+ T cell decline (p = 0.02, exact log-rank test comparing monotherapy to cART). The Kaplan-Meier estimate of probability of primary endpoint on 3TC/FTC at 28 weeks was 0.41 (standard error 0.14). There were no CDC class C events or deaths and no statistically significant difference in frequencies of adverse events between the arms.Non-adherent participants randomized to 3TC/FTC were more likely than those (...) Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial. Management of persistently non-adherent youth living with HIV (YLHIV) with virologic failure (VF) on combination antiretroviral therapy (cART) remains challenging. One strategy has been using 3TC/ FTC monotherapy (3TC/FTC), which in the presence of the M184V resistance mutation, does not suppress viral replication nor select

Full Text available with Trip Pro

2017 PLoS ONE Controlled trial quality: uncertain

7. CD4 Lymphocyte Enumeration and Hemoglobin Assessment Aid for Priority Decisions: A Multisite Evaluation of the BD FACSPrestoâ„¢ System (PubMed)

CD4 Lymphocyte Enumeration and Hemoglobin Assessment Aid for Priority Decisions: A Multisite Evaluation of the BD FACSPrestoâ„¢ System The BD FACSPresto™ system uses capillary and venous blood to measure CD4 absolute counts (CD4), %CD4 in lymphocytes, and hemoglobin (Hb) in approximately 25 minutes. CD4 cell count is used with portable CD4 counters in resource-limited settings to manage HIV/AIDS patients. A method comparison was performed using capillary and venous samples from seven clinical (...) linear regression and Bland-Altman methods), and for concordance around the clinical decision point. The coefficient of variation was estimated per site, instrument/operator, cartridge-lot and between-runs.For method comparison, 93% of the 720 samples were from HIV-positive and 7% from HIV-negative or normal subjects. CD4 and %CD4 T cells venous and capillary results gave slopes within 0.96-1.05 and R2 ≥0.96; Hb slopes were ≥1.00 and R2 ≥0.89. Variability across sites/operators gave %CV <5.8% for CD4

Full Text available with Trip Pro

2017 The open AIDS journal

8. The use of total lymphocyte count as a surrogate for low CD4+ T lymphocyte cell counts among HIV-1-infected women in Tanzania. (PubMed)

an absolute CD4 count < 200 cells/mm3 were determined for various clinically relevant cut points.TLC was not a good predictor of low CD4 cell counts during pregnancy or at least six months postpartum as exhibited by low ROC Area Under the Curve (AUCs) of .57 and .62 respectively. No other variable had the ability to predict CD4 < 200 cells/mm3.The use of TLC as a proxy for the estimation of low CD4 cell counts in a population of HIV-1-infected adults from sub-Saharan Africa was not substantiated (...) The use of total lymphocyte count as a surrogate for low CD4+ T lymphocyte cell counts among HIV-1-infected women in Tanzania. Human Immunodeficiency Virus type 1 (HIV-1) infection leads to a progressive decline in CD4+ T-lymphocyte (CD4) cells. Initiation of prophylaxis against Opportunistic infections in adults (CD4% used for children) and antiretroviral therapy is usually based on CD4 cell counts, but CD4 cell counts measurement is not affordable in most African countries.To examine whether

2010 East African journal of public health Controlled trial quality: uncertain

9. CCR5-modified CD4+ T Cells for HIV Infection

: SB-728-T Biological: Expanded unmodified autologous CD4+ T cells Phase 1 Phase 2 Detailed Description: This is a randomized clinical trial comparing the effect of infusing expanded autologous CD4+ T cells with or without ex vivo modification of the CCR5 gene by zinc finger nucleases among HIV-infected patients with plasma HIV RNA levels <50 copies/mL for at least 48 weeks and CD4+ T cell counts greater than 350 cells/µL. The main hypothesis is that the infusion of modified CD4+ T cells will lead (...) -treated with cyclophosphamide at a dose of 1 g/m2 before infusion. The primary outcome measure will be the change in the number of infectious units per million (IUPM) CD4+ T cells from study enrollment to 24 months after infusion of expanded CD4+ T cells. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 30 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Randomized

2018 Clinical Trials

10. Venetoclax (Venclyxto) - Chronic, B-Cell Lymphocytic Leukemia

Management Plan 114 2.8. Pharmacovigilance 124 2.9. Product information 124 2.9.1. User consultation 124 2.9.2. Additional monitoring 124 3. Benefit-Risk Balance 124 4. Recommendations 130 Assessment report EMA/725631/2016 Page 3/132 List of abbreviations AE adverse event AIHA autoimmune hemolytic anaemia ALC absolute lymphocyte count ALT alanine aminotransferase ANC absolute neutrophil count anti HBc hepatitis B core antibody anti HBs hepatitis B surface antibody aPTT activated partial thromboplastin (...) Venetoclax (Venclyxto) - Chronic, B-Cell Lymphocytic Leukemia 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 13 October 2016 EMA/725631/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Venclyxto

2017 European Medicines Agency - EPARs

11. Sysmex-XN 20 Analyser to Assess Lymphocyte Subsets and Other Haematological Parameters in Chronic/Acute Viral Infections

-Series' individual channels allow real-time reflex analysis, and uses a two stage process to classify the white blood count (WBC) sub-populations and detect the presence of abnormal reactive and malignant cells. In regards to lymphocytes in the peripheral blood, the machine has the capacity to distinguish activated from non-activated T-cell subsets using a very small volume of EDTA sample (88uL) (including remnant sample from a standard full blood count) with results available in 1.5 minutes (...) HCV, untreated HCV monoinfection or untreated HBV monoinfection, have a significant excess of activated lymphocytes as measured by D1+D2 on the XN WDF channel using the XN-20 analyser? Objectives: Primary: To assess whether participants who have chronic or acute viral infections have a significant excess of activated lymphocytes measured by the Sysmex-XN 20 analyser. Secondary: To compare, the absolute numbers and percentages of lymphocytes subsets as measured in the Sysmex-XN 20 analyser

2018 Clinical Trials

12. Chronic Lymphocytic Leukemia Treatment (PDQ®): Health Professional Version

or recommendations for making health care decisions. This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). General Information About Chronic Lymphocytic Leukemia (CLL) Incidence and Mortality Estimated new cases and deaths from CLL (...) in the United States in 2019:[ ] New cases: 20,720. Deaths: 3,930. CLL is a disorder of morphologically mature but immunologically less mature lymphocytes and is manifested by progressive accumulation of these cells in the blood, bone marrow, and lymphatic tissues.[ ] In this disorder, lymphocyte counts in the blood are usually greater than or equal to 5,000/mm 3 with a characteristic immunophenotype (CD5- and CD23-positive B cells).[ , ] As assays have become more sensitive for detecting monoclonal B-CLL

2016 PDQ - NCI's Comprehensive Cancer Database

13. Chronic Lymphocytic Leukemia Treatment (PDQ®): Health Professional Version

or recommendations for making health care decisions. This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). General Information About Chronic Lymphocytic Leukemia (CLL) Incidence and Mortality Estimated new cases and deaths from CLL (...) in the United States in 2019:[ ] New cases: 20,720. Deaths: 3,930. CLL is a disorder of morphologically mature but immunologically less mature lymphocytes and is manifested by progressive accumulation of these cells in the blood, bone marrow, and lymphatic tissues.[ ] In this disorder, lymphocyte counts in the blood are usually greater than or equal to 5,000/mm 3 with a characteristic immunophenotype (CD5- and CD23-positive B cells).[ , ] As assays have become more sensitive for detecting monoclonal B-CLL

2016 PDQ - NCI's Comprehensive Cancer Database

14. Performance Evaluation of the Becton Dickinson FACSPrestoâ„¢ Near-Patient CD4 Instrument in a Laboratory and Typical Field Clinic Setting in South Africa (PubMed)

, 135 patients were capillary-bled for CD4 testing on FACSPresto™, performed according to manufacturer instruction. Comparative statistical analyses against predicate PLG/CD4 method and industry standards were done using GraphPad Prism 6. It included Bland-Altman with 95% limits of agreement (LOA) and percentage similarity with coefficient of variation (%CV) analyses for absolute CD4 count (cells/μl) and CD4 percentage of lymphocytes (CD4%).In Phase-I, 179/217 samples yielded reportable results (...) with Presto™ using venous blood filled cartridges. Compared to predicate, a mean bias of 40.4±45.8 (LOA of -49.2 to 130.2) and %similarity (%CV) of 106.1%±7.75 (7.3%) was noted for CD4 absolute counts. In Phase-2 field study, 118/135 capillary-bled Presto™ samples resulted CD4 parameters. Compared to predicate, a mean bias of 50.2±92.8 (LOA of -131.7 to 232) with %similarity (%CV) 105%±10.8 (10.3%), and 2.87±2.7 (LOA of -8.2 to 2.5) with similarity of 94.7±6.5% (6.83%) noted for absolute CD4 and CD4

Full Text available with Trip Pro

2016 PloS one

15. Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

in Cohort 2 will receive 2.5 x 10^7/kg TIL 1383I TCR transduced T cells. Subjects in Cohort 3 will receive 7.5 x 10^7/kg TIL 1383I TCR transduced T cells. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 18 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes: A Phase 1b Study (...) skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for two years. Patients that have undergone immunotherapy targeting tyrosinase. Patients that have undergone immunotherapy in combination with non-myeloablative chemotherapy. Any of the following abnormal laboratory values Absolute neutrophil count less than 1.5 x 10^9/L Platelet count less than 100

2016 Clinical Trials

16. Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

hemolytic anemia or idiopathic thrombocytopenic purpura (ITP) are excluded; patients who have transfusion-dependent thrombocytopenia or bleeding/coagulation disorders that may increase the risk of life-threatening bleeding are excluded Eastern Cooperative Oncology Group (ECOG) performance status must be < 2 Patients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following: No evidence of co-infection with hepatitis B or C CD4+ cell count >= 400/mm^3 No evidence (...) , or poorly controlled inflammatory bowel disease affecting the small intestine are ineligible Absolute neutrophil count > 750 cells/mcL (0.75 x 10^9/L) Platelet count > 50,000 cells/mcL (50 × 10^9/L) Hemoglobin > 8.0 g/dL Total bilirubin =< 1.5 x upper limit of normal (ULN) (unless Gilbert's syndrome or disease infiltration of the liver is present) Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT

2014 Clinical Trials

17. Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

) Primary Purpose: Treatment Official Title: A Dose Escalation Study of Ibrutinib With Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Actual Study Start Date : May 28, 2013 Estimated Primary Completion Date : December 31, 2020 Estimated Study Completion Date : December 31, 2020 Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental (...) days prior to first dose of study drug, with the exception of pegylated G-CSF (pegfilgrastim) and darbopoeitin which require a 14-day period between dosing and first dose of study drug Absolute neutrophil count (ANC) >= 750 cells/uL (0.75 x 10^9/L) Platelets >= 50,000 cells/uL (50 x 10^9/L) Hemoglobin > 8 mg/dL Total bilirubin =< 1.5 x upper limit of normal (ULN) unless Gilbert's syndrome or disease infiltration of the liver is present Aspartate aminotransferase (AST) (serum glutamic oxaloacetic

2013 Clinical Trials

18. Tecfidera Lymphocyte Chart Review

Details: Drug: dimethyl fumarate delayed release capsules Other Names: DMF; Tecfidera BG00012 Outcome Measures Go to Primary Outcome Measures : Estimated absolute lymphocyte count (ALC) change from baseline following Tecfidera initiation [ Time Frame: 6 and 12 months ] Estimated CD4+ count change from baseline following Tecfidera initiation [ Time Frame: 6 and 12 months ] Estimated CD8+ count change from baseline following Tecfidera initiation [ Time Frame: 6 and 12 months ] Secondary Outcome Measures (...) : Raw absolute counts for leukocyte, lymphocyte, CD4+/CD8+ ratio following Tecfidera initiation [ Time Frame: 6 and 12 months ] Raw absolute counts for additional lymphocyte subsets (other than CD4+ and CD8+) [ Time Frame: 6 and 12 months ] Change from baseline for leukocyte, lymphocyte, CD4+/CD8+ ratio following Tecfidera initiation [ Time Frame: 6 and 12 months ] Change from baseline for additional lymphocyte subsets (other than CD4+and CD8+) following Tecfidera initiation [ Time Frame: 6 and 12

2015 Clinical Trials

19. Reference values of T lymphocyte subsets among health adults in Inner Mongolia Region (PubMed)

of Inner Mongolia Autonomous Region, flow cytometry was performed to determine the reference ranges for lymphocyte subsets (CD3 and CD4 cells) in 400 healthy multiracial adult population from 12 League Cities in Inner Mongolia Region, China. The basic information including age, gender, nationality and history was collected. There were significant differences in the absolute counting, percentage of CD3+T lymphocytes, and CD4+T lymphocyte percentage counting among different age groups. There were (...) significant differences in CD3+, CD4+T lymphocyte percentage in the groups with different genders. There were significant differences in CD3+T lymphocyte percentage count, absolute count of CD4+T lymphocytes and CD4+T lymphocyte percentage counting in the group with ages of 16-20. There were dramatic differences in CD3+T lymphocyte percentage count and CD4+T lymphocyte percentage counting in the group with ages of 31-40. There were significant differences in CD4+T lymphocyte percentage counting

Full Text available with Trip Pro

2015 International journal of clinical and experimental medicine

20. Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)

. In RA patients, B lymphocytes count before each rituximab course should be done to prevent opportunistic infections (Pham, Fautrel et al. 2008). In a recent retrospective study, a CD4+ T-lymphocytes depletion was observed after a first course of rituximab in RA patients. The absolute CD4+ number at week 12 was 37% (±33) of the baseline value, leading to < 200 cells/µL in 5% of patients. Interestingly the absence of CD4+ T-lymphocytes depletion was observed in clinical non-responders, suggesting (...) % of patients have an insufficient or absence of response to rituximab at week 24. In a recent retrospective study, a CD4+ T-lymphocytes depletion was observed after a first course of rituximab in RA patients. The absolute CD4+ number at week 12 was 37% (±33) of the baseline value, leading to < 200 cells/µL in 5% of patients. Interestingly the absence of CD4+ T-lymphocytes depletion was observed in clinical non-responders, suggesting the involvement of T-lymphocytes in the mechanism of action of rituximab

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>